EHVA
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novelprophylactic and therapeutic vaccine candidates
Objective
The generation of novel vaccine candidates in the field of prophylactic and therapeutic vaccines inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses (for therapeutic vaccines).
Description
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at an early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.
AIGHD Research Lead
Dr. Godelieve de Bree
Partners
Institut national de la santé et de la recherche médicale
Hospices Cantonaux Chuv
Sanofi Pasteur
Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer
Heinrich-Pette Institut Leibniz Institut Fuer Experimentelle Virologie
Imperial College of Science, Technology and Medicine
Istituto Superiore di Sanità
Universitaet Regensburg
Karolinska Institutet
Universitaet Zuerich
Fondazione per l’Istituto di Ricerca in Biomedicina
Universitaetsklinikum Hamburg-Eppendorf
The Chancellor, Masters and Scholars of the University of Oxford
Universite Joseph Fourier Grenoble
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Stichting Biomedical Primate Research Center
Klinkikum Der Universitat Munchen
Medizinische Universität Innsbruck
Agencia Estatal Consejo Superior De Investigaciones Cientificas
Université de Lausanne
Erasmus Universitair Medisch Centrum Rotterdam
Stichting International AIDS Vaccine Initiative
FIT Biotech Oy
EuroVacc Foundation
Fred Hutchinson Cancer Research Center
Commissariat A L Energie Atomique Et Aux Energies Alternatives
Universitaet Bern
Janssen
Uganda Virus Research Institute
National Institute for Medical Research
Instituto Nacional de Saude
PACCI, University College London
The University of Liverpool
The General Hospital Corporation
Vrije Universiteit Brussel
Istituto Nazionale Malattie Infettive L.Spallanzani – IRCCS
European AIDS Treatment Group
Inserm Transfert
Funders
European Commission
Countries
France, Switzerland, Spain, Germany, UK, Italy, Sweden, Netherlands, Austria, Finland, Uganda, Tanzania, Mozambique, US, Cote d’Ivoire, Belgium